You are here: Industry Insights > mRNA-1273

News List

Moderna initiates Phase III trial of COVID-19 vaccine candidate europeanpharmaceuticalreview
August 04, 2020
The first patients have been dosed in Moderna’s Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates worldpharmanews
July 30, 2020
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2 ...
U.S. Invests $472mn More in Moderna contractpharma
July 28, 2020
Expansion of BARDA deal supports mRNA-1273 clinical development plan including 30,000 participant Phase 3 COVE study conducted in collaboration with NIH.
Moderna begins Phase 3 trials of its COVID-19 vaccine candidate expresspharma
July 28, 2020
The randomised, placebo-controlled trial is expected to include approximately 30,000 participants in the US.
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response europeanpharmaceuticalreview
July 16, 2020
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
Moderna teams up with ROVI to provide Covid-19 vaccine outside US pharmaceutical-technology
July 13, 2020
US-based biotechnology firm Moderna has partnered with European pharmaceutical company Laboratorios Farmacéuticos Rovi (ROVI) for finish-fill manufacturing of its Covid-19 vaccine candidate, mRNA-1273.
Moderna and Catalent announce collaboration for COVID-19 vaccine candidate expresspharma
June 28, 2020
Catalent to provide vial filling and packaging capacity, as well as additional staffing to support the production of an initial 100 million doses of the vaccine candidate from its facility in Bloomington, Indiana in the US.
Moderna’s Phase I Interim Data of mRNA-1273 Shows Promise contractpharma
May 27, 2020
Dose dependent increases in immunogenicity against SARS-CoV-2 were seen across the three dose levels.
Moderna’s Covid-19 vaccine shows significant effect in early human trial pharmaceutical-business-review
May 21, 2020
Moderna announced that its mRNA-1273 vaccine candidate against novel coronavirus (SARS-CoV-2) has demonstrated a significant effect in an early human trial.
Moderna gets FDA fast track status for mRNA vaccine against novel coronavirus pharmaceutical-business-review.
May 14, 2020
Moderna has secured fast track designation from the US Food and Drug Administration (FDA) for its mRNA-1273, the mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).

Previous page 1 2 3 4 5 6 Next page